Search

Your search keyword '"Haenel, M"' showing total 199 results
Start Over Author "Haenel, M"
199 results on '"Haenel, M"'

1. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients

Author

Röllig, C., Kramer, M., Gabrecht, M., Hänel, M., Herbst, R., Kaiser, U., Schmitz, N., Kullmer, J., Fetscher, S., Link, H., Mantovani-Löffler, L., Krümpelmann, U., Neuhaus, T., Heits, F., Einsele, H., Ritter, B., Bornhäuser, M., Schetelig, J., Thiede, C., Mohr, B., Schaich, M., Platzbecker, U., Schäfer-Eckart, K., Krämer, A., Berdel, W.E., Serve, H., Ehninger, G., and Schuler, U.S.

Published
2018
Full Text
View/download PDF

5. 681P OPTIM: A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck – AIO-KHT-0117

Author

Gruenwald, V., primary, Alt, J., additional, Tometten, M., additional, Haenel, M., additional, Ivanyi, P., additional, Schuch, G., additional, Klinghammer, K., additional, Gutsche, K., additional, Hasenkamp, J., additional, Hapke, G., additional, Mänz, M., additional, Weichert, W., additional, and Hahn, D.A., additional

Published
2022
Full Text
View/download PDF

6. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

Author

Mai, E K, Bertsch, U, Dürig, J, Kunz, C, Haenel, M, Blau, I W, Munder, M, Jauch, A, Schurich, B, Hielscher, T, Merz, M, Huegle-Doerr, B, Seckinger, A, Hose, D, Hillengass, J, Raab, M S, Neben, K, Lindemann, H-W, Zeis, M, Gerecke, C, Schmidt-Wolf, I G H, Weisel, K, Scheid, C, Salwender, H, and Goldschmidt, H

Published
2015
Full Text
View/download PDF

7. P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO-HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT

Author

Tilmont, R., primary, Yakoub-Agha, I., additional, Eikema, D.-J., additional, Zinger, N., additional, Haenel, M., additional, Schaap, N., additional, Herrera Arroyo, C., additional, Schuermans, C., additional, Bethge, W., additional, Engelhardt, M., additional, Kuball, J., additional, Michieli, M., additional, Schub, N., additional, Wilson, K. M. O., additional, Bourhis, J. H., additional, Mateos, M. V., additional, Robin, N., additional, Jost, E., additional, Kröger, N., additional, Moraleda, J. M., additional, Sica, S., additional, Hayden, P. J., additional, Beksac, M., additional, Schönland, S., additional, and Manier, S., additional

Published
2022
Full Text
View/download PDF

8. Subcutaneous Daratumumab (DARA SC) with Standard-ofCare (SoC) in Multiple Myeloma (MM) across therapy lines in phase 2 PLEIADES: Initial results with SoC Carfilzomib/Dexamethasone (D-Kd) and updated results with SoC Bortezomib/Melphalan/Prednisone (D-VMP) or Lenalidomide/Dexamethasone (D-Rd)

Author

Goldschmidt, H, Chari, A, Haenel, M, Oriol, A, Rodriguez-Otero, P, McCarthy, H, Suzuki, K, Hungria, V, Balari, AS, Clement-Filliatre, L, Hulin, C, Magen, H, Iida, S, Maisnar, V, Karlin, L, Pour, L, Touzeau, C, Yang, S, Kosh, M, Delioukina, M, Heuck, C, and Moreau, P

Published
2021

9. 10-year follow-up of the R-MegaCHOEP trial: conditional survival analysis reveals 1-year progression-free survival as crucial prognostic factor for long-term outcome in young high-risk patients with aggressive B-cell lymphoma

Author

Frontzek, F., Ziepert, M., Nickelsen, M., Altmann, B., Glass, B., Haenel, M., Truemper, L., Held, G., Bentz, M., Borchmann, P., Dreyling, M., Viardot, A., Kroschinsky, F., Metzner, B., Staiger, A. M., Horn, H., Ott, G., Rosenwald, A., Loeffler, M., Lenz, G., Schmitz, N., Frontzek, F., Ziepert, M., Nickelsen, M., Altmann, B., Glass, B., Haenel, M., Truemper, L., Held, G., Bentz, M., Borchmann, P., Dreyling, M., Viardot, A., Kroschinsky, F., Metzner, B., Staiger, A. M., Horn, H., Ott, G., Rosenwald, A., Loeffler, M., Lenz, G., and Schmitz, N.

Published
2020

10. Mobilization of autologous stem cells under induction therapy with Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone (Isa-KRd) in high risk myeloma patients: First results of the GMMG-CONCEPT trial

Author

Asemissen, A. M., Scheid, C., Leypoldt, L., Schieferdecker, A., Besemer, B., Blau, I. -W., Goerner, M., Ko, Y. -D., Haenel, M., Duerig, J., Staib, P., Salwender, H., Mann, C., Munder, M., Graeven, U., Peceny, R., Lutz, R., Zago, M., Benner, A., Tichy, D., Bokemeyer, C., Goldschmidt, H., Weisel, K., Asemissen, A. M., Scheid, C., Leypoldt, L., Schieferdecker, A., Besemer, B., Blau, I. -W., Goerner, M., Ko, Y. -D., Haenel, M., Duerig, J., Staib, P., Salwender, H., Mann, C., Munder, M., Graeven, U., Peceny, R., Lutz, R., Zago, M., Benner, A., Tichy, D., Bokemeyer, C., Goldschmidt, H., and Weisel, K.

Published
2020

11. Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma

Author

Davies, A, Trask, P, Demeter, J, Florschuetz, A, Haenel, M, Kinoshita, T, Pettengell, R, Quach, H, Robinson, S, Sadullah, S, Sancho, J-M, Udvardy, M, Witzens-Harig, M, Knapp, A, Liu, W, Davies, A, Trask, P, Demeter, J, Florschuetz, A, Haenel, M, Kinoshita, T, Pettengell, R, Quach, H, Robinson, S, Sadullah, S, Sancho, J-M, Udvardy, M, Witzens-Harig, M, Knapp, A, and Liu, W

Abstract

Health-related quality of life was a secondary endpoint in the phase III GALLIUM study in previously untreated patients with follicular lymphoma who were treated with rituximab- or obinutuzumab-chemotherapy. Patients were randomized 1:1 to receive induction therapy with obinutuzumab- or rituximab-chemotherapy and maintenance in responders. Health-related quality of life was assessed using the Functional Assessment of Cancer Treatment-Lymphoma questionnaire, incorporating well-being and lymphoma-specific subscales. Assessments were performed at baseline, and during induction, maintenance, and follow-up (maximum 84 months). Clinically meaningful responses were defined by minimally important difference values. Of 1202 randomized patients (median follow-up 57.4 months), 557/601 (92.7%; obinutuzumab-chemotherapy) and 548/601 (91.2%; rituximab-chemotherapy) completed all Functional Assessment of Cancer Treatment-Lymphoma scales at baseline. Mean baseline health-related quality of life scores were similar between both arms, with all patients having some functional impairment and lymphoma symptoms. Over the course of treatment, mean health-related quality of life remained similar in both arms. Equal proportions of patients in both arms achieved minimally important difference by the Functional Assessment of Cancer Treatment-Lymphoma lymphoma-specific subscale and summary scales throughout induction, maintenance, and follow-up. On each summary scale, ~ 50% of patients in each arm achieved minimally important difference by maintenance month 2. In GALLIUM, similar improvements in health-related quality of life were seen with obinutuzumab- and rituximab-chemotherapy, suggesting that both treatments reduced lymphoma-related symptoms, and treatment-related side effects did not abrogate these improvements in well-being. ClinicalTrials.gov identifier: NCT01332968.

Published
2020

14. Optimization of imatinib therapy by combination. Final results of the pilot phase of the randomized German CML Study IV: V279

Author

Leitner, A., Sauele, S., Pletsch, N., Lauseker, M., Jung-Munkwitz, S., Proetel, U., Müller, M. C., Haferlach, C., Schlegelberger, B., Schnittger, S., Hanfstein, B., Pfirrmann, M., Ehninger, G., Fischer, T., Hossfeld, D., Kolb, H.-J., Krause, S., Nerl, C., Pralle, H., Gratwohl, A., Baerlocher, G., Heimpel, H., Balleisen, L., Einsele, H., Falge, C., Haenel, M., Pfreundschuh, M., Kanz, L., Stegelmann, F., Köhne, C. H., Kremers, S., Spiekermann, K., Koschmieder, S., Waller, C. F., Bentz, M., Hochhaus, A., Hasford, J., and Hehlmann, R.

Published
2010

15. High dose imatinib 800mg induces higher major molecular response (MMR) rates than imatinib 400 mg ± IFN in newly diagnosed BCR/ABL positive chronic phase CML: A randomized comparison of the German CMLStudy IV: V276

Author

Sauele, S., Lauseker, M., Jung-Munkwitz, S., Leitner, A., Proetel, U., Müller, M. C., Pletsch, N., Haferlach, C., Schnittger, S., Hanfstein, B., Schlegelberger, B., Waller, C., Neubauer, A., Kanz, L., Haenel, M., Mayer, J., Stegelmann, F., Koschmieder, S., Pfirrmann, M., Ehninger, G., Fischer, T., Hossfeld, D., Kolb, H.-J., Krause, S., Nerl, C., Pralle, H., Gratwohl, A., Baerlocher, G., Heimpel, H., Hasford, J., Hochhaus, A., and Hehlmann, R.

Published
2010

16. Evolution of blast crisis (BC) in chronic myeloid leukemia (CML) in the imatinib-era: A rare but early event; need for rapid detection. Results of the German CML Study IV.: V281

Author

Sauele, S., Lauseker, M., Pfirrmann, M., Leitner, A., Erben, P., Müller, M. C., Proetel, U., Jung-Munkwitz, S., Pletsch, N., Stegelmann, F., Ho, A. D., Schlimok, G., Lindemann, W., Beelen, D., Haenel, M., Haferlach, C., Schlegelberger, B., Schnittger, S., Gratwohl, A., Hasford, J., Hochhaus, A., and Hehlmann, R.

Published
2010

18. Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA

Author

Murawski, N., Poeschel, V., Ziepert, M., Altmann, B., Dreyling, M., Borchmann, P., Viardot, A., Luminari, S., Witzens-Harig, M., Dierlamm, J., Haenel, M., Truemper, L., Metzner, B., Lengfelder, E., Keller, U., Ruebe, C., Berdel, C., Schmitz, N., Held, G., Pfreundschuh, M., Murawski, N., Poeschel, V., Ziepert, M., Altmann, B., Dreyling, M., Borchmann, P., Viardot, A., Luminari, S., Witzens-Harig, M., Dierlamm, J., Haenel, M., Truemper, L., Metzner, B., Lengfelder, E., Keller, U., Ruebe, C., Berdel, C., Schmitz, N., Held, G., and Pfreundschuh, M.

Published
2018

19. Pomalidomide, cyclophosphamide and dexamethasone in case of suboptimal response to pomalidomide and dexamethasone alone in relapsed and/or refractory multiple myeloma: Final results of the GMMG-PERSPECTIVE trial

Author

Weisel, K., Salwender, H., Scheid, C., Zago, M., Besemer, B., Haenel, M., Duerig, J., Munder, M., Lindemann, H. -W, Seckinger, A., Kunz, C., Benner, A., Hose, D., Jauch, A., Kanz, L., Goldschmidt, H., Weisel, K., Salwender, H., Scheid, C., Zago, M., Besemer, B., Haenel, M., Duerig, J., Munder, M., Lindemann, H. -W, Seckinger, A., Kunz, C., Benner, A., Hose, D., Jauch, A., Kanz, L., and Goldschmidt, H.

Published
2018

20. MAGNETIC RESONANCE IMAGING BEFORE AND AFTER UPFRONT AUTOLOGOUS TRANSPLANTATION IDENTIFIES PATIENTS WITH ADVERSE OUTCOME BUT RESPONSE TO TREATMENT WITHIN THE PROSPECTIVE GMMG MM5 PHASE III TRIAL

Author

Merz, M., Hielscher, T., Seckinger, A., Jauch, A., Mai, E. K., Bertsch, U., Raab, M. S., Neben, K., Salwender, H., Blau, I. W., Lindemann, H. W., Duerig, J., Scheid, C., Haenel, M., Weisel, K., Delorme, S., Kauczor, H. U., Hose, D., Goldschmidt, H., Hillengass, J., Merz, M., Hielscher, T., Seckinger, A., Jauch, A., Mai, E. K., Bertsch, U., Raab, M. S., Neben, K., Salwender, H., Blau, I. W., Lindemann, H. W., Duerig, J., Scheid, C., Haenel, M., Weisel, K., Delorme, S., Kauczor, H. U., Hose, D., Goldschmidt, H., and Hillengass, J.

Published
2018

21. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial

Author

Winston, Drew J, primary, Mullane, Kathleen M, additional, Cornely, Oliver A, additional, Boeckh, Michael J, additional, Brown, Janice Wes, additional, Pergam, Steven A, additional, Trociukas, Igoris, additional, Žák, Pavel, additional, Craig, Michael D, additional, Papanicolaou, Genovefa A, additional, Velez, Juan D, additional, Panse, Jens, additional, Hurtado, Kimberly, additional, Fernsler, Doreen A, additional, Stek, Jon E, additional, Pang, Lei, additional, Su, Shu-Chih, additional, Zhao, Yanli, additional, Chan, Ivan S F, additional, Kaplan, Susan S, additional, Parrino, Janie, additional, Lee, Ingi, additional, Popmihajlov, Zoran, additional, Annunziato, Paula W, additional, Arvin, Ann, additional, Basso, AC, additional, Bonvehi, P, additional, Cerana, S, additional, Dictar, MO, additional, Campbell, P, additional, Playford, G, additional, Sasadeusz, J, additional, Maertens, J, additional, Poire, X, additional, Sellesag, D, additional, Schots, R, additional, Theunissen, K, additional, Willems, E, additional, Alves, RS, additional, Camargo, JFC, additional, Castro, NS, additional, Maria Fogliatto, L, additional, Rodrigo, O, additional, Courture, F, additional, McGeer, A, additional, Miller, M, additional, Combariza, JF, additional, Sossa, CL, additional, Velez, JD, additional, Nemet, D, additional, Ostojic Kolonic, S, additional, Jebavy, L, additional, Mayer, J, additional, Novak, J, additional, Pohlreich, D, additional, Maldonado, B, additional, Gastinne, T, additional, Karlin, L, additional, Launay, O, additional, Cornely, OA, additional, Duerk, HA, additional, Haenel, M, additional, Heinz, W, additional, Kaufmann, M, additional, Panse, J, additional, Teschner, D, additional, Verbeek, M, additional, Wulf, G, additional, Aviv, F, additional, Grisariu, S, additional, Nagler, A, additional, Yeshurun, M, additional, Bosi, A, additional, Corradini, P, additional, Martinelli, G, additional, Onida, F, additional, Rambaldi, A, additional, Velardi, A, additional, Trociukas, I, additional, Gomez, AD, additional, Wondergem, MJ, additional, Ypma, PF, additional, Fanilla, E, additional, Moreno Larrea, MDC, additional, Abecasis, MM, additional, Ferreira, RB, additional, Geraldes, C, additional, Castro, J, additional, Afanasyev, BV, additional, Kruchkova, IV, additional, Zaritskiy, AY, additional, Cheong, JW, additional, Kim, SJ, additional, Lee, DG, additional, Yoon, SS, additional, Aguado Bueno, B, additional, Jarque Ramos, I, additional, Solano Vercet, C, additional, Cherif, H, additional, Ljungman, P, additional, Vaht, K, additional, Cook, G, additional, Kanfer, E, additional, Milligan, DW, additional, Parker, A, additional, Akard, L, additional, Bachier, C, additional, Ball, ED, additional, Betts, FR, additional, Braunschweig, I, additional, Brown, JM, additional, Carroll, MP, additional, Chandrasekar, PH, additional, Collins, R, additional, Cooper, B, additional, Craig, M, additional, D'Cunha, N, additional, Donato, ML, additional, Essell, J, additional, Flomenberg, P, additional, Freifeld, A, additional, Freytes, C, additional, Guarino, MJ, additional, Hall, MC, additional, Heimenz, JW, additional, High, KP, additional, Isola, LM, additional, Kaminer, L, additional, Klein, LM, additional, Janakiraman, N, additional, Kane, K, additional, Komanduri, K, additional, Krijanovski, OI, additional, Lawrence, SJ, additional, Leis, JF, additional, Lill, M, additional, Longo, WL, additional, Lynch, JP, additional, Mattar, BI, additional, Mehta, J, additional, Mullane, KM, additional, Nathan, S, additional, Papanicolaou, GA, additional, Pergam, SA, additional, Roy, V, additional, Rybka, W, additional, Safah, H, additional, Saltzman, D, additional, Segal, GM, additional, Selby, GB, additional, Schuster, MW, additional, Shoham, S, additional, Sloan, JM, additional, Strasfeld, LM, additional, Styler, M, additional, Sullivan, K, additional, Tse, W, additional, Vance, EA, additional, Winston, DJ, additional, and Yanovich, S, additional

Published
2018
Full Text
View/download PDF

22. Autologous stem cell transplantation (ASCT) or whole-brain radiotherapy (WBRT) as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with newly diagnosed primary cns lymphoma (PCNSL): results of the IELSG32 randomized Phase II Trial

Author

Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., La Rosee, P., Binder, M., Fabbri, A., Torri, V., Minacapelli, E., Falautano, M., Ilariucci, F., Ambrosetti, A., Roth, A., Hemmaway, C., Johnson, P., Linton, K. M., Pukrop, T., Gorlov, J. S., Balzarotti, M., Hess, G., Keller, U., Stilgenbauer, S., Panse, J., Tucci, A., Orsucci, L., Pisani, F., Levis, A., Krause, S., Schmoll, H. J., Hertenstein, B., Zaccaria, A., Guarini, A., Atta, J., Bassan, R., Cervetti, J., Elter, T., Enggaard, L., Haenel, M., Kneba, M., Liberati, M., Martelli, M., Martens, U., Morra, E., Pinto, A., Zaja, F., Ponzoni, M., Deckert, M., Politi, L. S., Finke, J., Reni, M., Cavalli, F., Zucca, E., Illerhaus, G., Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., La Rosee, P., Binder, M., Fabbri, A., Torri, V., Minacapelli, E., Falautano, M., Ilariucci, F., Ambrosetti, A., Roth, A., Hemmaway, C., Johnson, P., Linton, K. M., Pukrop, T., Gorlov, J. S., Balzarotti, M., Hess, G., Keller, U., Stilgenbauer, S., Panse, J., Tucci, A., Orsucci, L., Pisani, F., Levis, A., Krause, S., Schmoll, H. J., Hertenstein, B., Zaccaria, A., Guarini, A., Atta, J., Bassan, R., Cervetti, J., Elter, T., Enggaard, L., Haenel, M., Kneba, M., Liberati, M., Martelli, M., Martens, U., Morra, E., Pinto, A., Zaja, F., Ponzoni, M., Deckert, M., Politi, L. S., Finke, J., Reni, M., Cavalli, F., Zucca, E., and Illerhaus, G.

Published
2017

23. ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10-YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV

Author

Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H-J, Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Fabarius, A., Haferlach, C., Schlegelberger, B., Mueller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Burchert, A., Voskanyan, A., Rinaldetti, S., Goebeler, M., Dengler, J., Ho, A., Falge, C., Kanz, L., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Spiekermann, K., Fuchs, R., Scheid, C., Haenel, M., Koehne, C-H, Bruemmendorf, H., Lindemann, H-W, Berdel, W. E., Staib, P., Balleisen, L., Brossart, P., Schenk, M., Zankovich, R., Geer, T., Hertenstein, B., Bildat, S., Hochhaus, A., Hasford, J., Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H-J, Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Fabarius, A., Haferlach, C., Schlegelberger, B., Mueller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Burchert, A., Voskanyan, A., Rinaldetti, S., Goebeler, M., Dengler, J., Ho, A., Falge, C., Kanz, L., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Spiekermann, K., Fuchs, R., Scheid, C., Haenel, M., Koehne, C-H, Bruemmendorf, H., Lindemann, H-W, Berdel, W. E., Staib, P., Balleisen, L., Brossart, P., Schenk, M., Zankovich, R., Geer, T., Hertenstein, B., Bildat, S., Hochhaus, A., and Hasford, J.

Published
2017

24. Radiotherapy to bulky disease PET-negative after immunochemotherapy can be spared in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL > 60 study of the DSHNHL

Author

Pfreundschuh, M., Christofyllakis, K., Altmann, B., Ziepert, M., Haenel, M., Viardot, A., Neubauer, A., Held, G., Truemper, L., Schmidt, C., Kanz, L., Hallek, M., Schmitz, N., Heintges, T., Koelbel, C., Schneider, G., Ruebe, C., Hellwig, D., Poeschel, V., Murawski, N., Pfreundschuh, M., Christofyllakis, K., Altmann, B., Ziepert, M., Haenel, M., Viardot, A., Neubauer, A., Held, G., Truemper, L., Schmidt, C., Kanz, L., Hallek, M., Schmitz, N., Heintges, T., Koelbel, C., Schneider, G., Ruebe, C., Hellwig, D., Poeschel, V., and Murawski, N.

Published
2017

25. Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy

Author

Murawski, N., Amam, J., Altmann, B., Ziepert, M., Haenel, M., Viardot, A., Neubauer, A., Held, G., Truemper, L., Schmidt, C., Kanz, L., Hallek, M., Schmitz, N., Heintges, T., Koelbel, C., Poeschel, V., Pfreundschuh, M., Murawski, N., Amam, J., Altmann, B., Ziepert, M., Haenel, M., Viardot, A., Neubauer, A., Held, G., Truemper, L., Schmidt, C., Kanz, L., Hallek, M., Schmitz, N., Heintges, T., Koelbel, C., Poeschel, V., and Pfreundschuh, M.

Published
2017

26. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Author

Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Bruemmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Mueller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spiess, B., Balleisen, L., Goebeler, M. C., Haenel, M., Ho, A., Dengler, J., Falge, C., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Koehne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, M., Spiekermann, K., Berdel, W. E., Mueller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, B., Fuchs, R., Wernli, M., Schlegel, F., Schlag, R., de Wit, M., Truemper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schaefer, E., Hochhaus, A., Hasford, J., Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Bruemmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Mueller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spiess, B., Balleisen, L., Goebeler, M. C., Haenel, M., Ho, A., Dengler, J., Falge, C., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Koehne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, M., Spiekermann, K., Berdel, W. E., Mueller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, B., Fuchs, R., Wernli, M., Schlegel, F., Schlag, R., de Wit, M., Truemper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schaefer, E., Hochhaus, A., and Hasford, J.

Abstract

Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n = 400) could be optimized by doubling the dose (n = 420), adding interferon (IFN) (n = 430) or cytarabine (n = 158) or using IM after IFN-failure (n = 128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-year overall survival was 82%, 10-year progression-free survival was 80% and 10-year relative survival was 92%. Survival between IM400 mg and any experimental arm was not different. In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization. Patients reaching the molecular response milestones at 3, 6 and 12 months had a significant survival advantage. For responders, monotherapy with IM400 mg provides a close to normal life expectancy independent of the time to response. Survival is more determined by patients' and disease factors than by initial treatment selection. Although improvements are also needed for refractory disease, more life-time can currently be gained by carefully addressing non-CML determinants of survival.

Published
2017

27. RADIOTHERAPY TO BULKY DISEASE PET-NEGATIVE AFTER IMMUNOCHEMOTHERAPY CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF a PLANNED INTERIM ANALYSIS OF THE FIRST 187 PATIENTS WITH BULKY DISEASE TREATED IN THE OPTIMAL > 60 STUDY OF THE DSHNHL

Author

Pfreundschuh, M., primary, Christofyllakis, K., additional, Altmann, B., additional, Ziepert, M., additional, Haenel, M., additional, Viardot, A., additional, Neubauer, A., additional, Held, G., additional, Truemper, L., additional, Dreyling, M., additional, Kanz, L., additional, Hallek, M., additional, Schmitz, N., additional, Heintges, T., additional, Kölbel, C., additional, Buecker, A., additional, Ruebe, C., additional, Hellwig, D., additional, Berdel, C., additional, Poeschel, V., additional, and Murawski, N., additional

Published
2017
Full Text
View/download PDF

28. ANTI-INFECTIVE PROPHYLAXIS WITH ACICLOVIR AND COTRIMOXAZOLE SIGNIFICANTLY REDUCES THE RATE OF INFECTIONS AND THERAPY-ASSOCIATED DEATHS IN ELDERLY PATIENTS WITH DLBCL UNDERGOING R-CHOP IMMUNOCHEMOTHERAPY

Author

Murawski, N., primary, Amam, J., additional, Altmann, B., additional, Ziepert, M., additional, Haenel, M., additional, Viardot, A., additional, Neubauer, A., additional, Held, G., additional, Truemper, L., additional, Dreyling, M., additional, Kanz, L., additional, Hallek, M., additional, Schmitz, N., additional, Heintges, T., additional, Koelbel, C., additional, Poeschel, V., additional, and Pfreundschuh, M., additional

Published
2017
Full Text
View/download PDF

29. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

Author

Merz, M., primary, Salwender, H., additional, Haenel, M., additional, Mai, E. K., additional, Bertsch, U., additional, Kunz, C., additional, Hielscher, T., additional, Blau, I. W., additional, Scheid, C., additional, Hose, D., additional, Seckinger, A., additional, Jauch, A., additional, Hillengass, J., additional, Raab, M. S., additional, Schurich, B., additional, Munder, M., additional, Brossart, P., additional, Gerecke, C., additional, Lindemann, H.-W., additional, Zeis, M., additional, Weisel, K., additional, Duerig, J., additional, and Goldschmidt, H., additional

Published
2016
Full Text
View/download PDF

30. EFFICIENCY AND TOXICITY OF CYCLOPHOSPHAMIDE BASED STEM CELL MOBILIZATION IN RELAPSED MULTIPLE MYELOMA PATIENTS: OBSERVATIONS FROM THE ONGOING PHASE III TRIAL RELAPSE

Author

Baertsch, M., Wuchter, P., Schlenzka, J., Weisel, K., Noppeney, R., Martin, H., Lindemann, H., Haenel, M., Nogai, A., Scheid, C., Salwender, H., Fenk, R., Graeven, U., Reimer, P., Schmidt-Hieber, M., Goerner, M., Schmidt-Wolf, I., Klein, S., Ho, A., Goldschmidt, H., Baertsch, M., Wuchter, P., Schlenzka, J., Weisel, K., Noppeney, R., Martin, H., Lindemann, H., Haenel, M., Nogai, A., Scheid, C., Salwender, H., Fenk, R., Graeven, U., Reimer, P., Schmidt-Hieber, M., Goerner, M., Schmidt-Wolf, I., Klein, S., Ho, A., and Goldschmidt, H.

Published
2015

31. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

Author

Mai, E. K., Bertsch, U., Duerig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W, Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H., Goldschmidt, H., Mai, E. K., Bertsch, U., Duerig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W, Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H., and Goldschmidt, H.

Abstract

We aimed at demonstrating non-inferiority of bortezomib/cyclophosphamide/dexamethasone (VCD) compared to bortezomib/doxorubicin/dexamethasone (PAd) induction therapy with respect to very good partial response rates or better (>= VGPR) in 504 newly diagnosed, transplant-eligible multiple myeloma patients. VCD was found to be non-inferior to PAd with respect to >= VGPR rates (37.0 versus 34.3%, P = 0.001). The rates of progressive disease (PD) were 0.4% (VCD) versus 4.8% (PAd; P = 0.003). In the PAd arm, 11 of 12 patients with PD had either renal impairment (creatinine >= 2 mg/dl) at diagnosis or the cytogenetic abnormality gain 1q21, whereas no PD was observed in these subgroups in the VCD arm. Leukocytopenia/neutropenia (>= 3 degrees) occurred more frequently in the VCD arm (35.2% versus 11.3%, P<0.001). Neuropathy rates (>= 2 degrees) were higher in the PAd group (14.9 versus 8.4%, P = 0.03). Serious adverse events, both overall and those related to thromboembolic events, were higher in the PAd group (32.7 versus 24.0%, P = 0.04 and 2.8 versus 0.4%, P = 0.04). Stem cell collection was not impeded by VCD. VCD is as effective as PAd in terms of achieving >= VGPR rates with fewer PD and has a favorable toxicity profile. Therefore, VCD is preferable to PAd as induction therapy.

Published
2015

32. DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapy

Author

Tschanter, P., Krug, U., Fueller, M., Klein, M., Goellner, S., Rohde, C., Roellig, C., Thiede, C., Lilly, M. A., Haack, B., Koschmieder, A., Stelljes, M., Dugas, M., Koschmieder, S., Gerss, J., Butterfass-Bahloul, T., Wagner, R., Eveslage, M., Thiem, U., Krause, S. W., Kaiser, U., Kunzmann, V, Steffen, B., Noppeney, R., Herr, W., Baldus, C. D., Schmitz, N., Goetze, K., Reichle, A., Kaufmann, M., Neubauer, A., Schaefer-Eckart, K., Haenel, M., Peceny, R., Frickhofen, N., Kiehl, M., Giagounidis, A., Goerner, M., Repp, R., Link, H., Kiani, A., Naumann, R., Bruemmendorf, T. H., Serve, H., Ehninger, G., Berdel, W. E., Mueller-Tidow, C., Tschanter, P., Krug, U., Fueller, M., Klein, M., Goellner, S., Rohde, C., Roellig, C., Thiede, C., Lilly, M. A., Haack, B., Koschmieder, A., Stelljes, M., Dugas, M., Koschmieder, S., Gerss, J., Butterfass-Bahloul, T., Wagner, R., Eveslage, M., Thiem, U., Krause, S. W., Kaiser, U., Kunzmann, V, Steffen, B., Noppeney, R., Herr, W., Baldus, C. D., Schmitz, N., Goetze, K., Reichle, A., Kaufmann, M., Neubauer, A., Schaefer-Eckart, K., Haenel, M., Peceny, R., Frickhofen, N., Kiehl, M., Giagounidis, A., Goerner, M., Repp, R., Link, H., Kiani, A., Naumann, R., Bruemmendorf, T. H., Serve, H., Ehninger, G., Berdel, W. E., and Mueller-Tidow, C.

Published
2015

33. Comparative assessment of myeloma response to induction treatment in the GMMG MM5 study using IMWG criteria and hevylite assay

Author

Scheid, C., Hose, D., Bertsch, U., Hielscher, T., Kunz, C., Salwender, H., Haenel, M., Merz, M., Mai, E. K., Schurich, B., Munder, M., Schmidt-Wolf, I, Gerecke, C., Lindemann, W., Zeis, M., Weisel, K., Duerig, J., Jauch, A., Peters-Regehr, T., Zorn, M., Goldschmidt, H., Scheid, C., Hose, D., Bertsch, U., Hielscher, T., Kunz, C., Salwender, H., Haenel, M., Merz, M., Mai, E. K., Schurich, B., Munder, M., Schmidt-Wolf, I, Gerecke, C., Lindemann, W., Zeis, M., Weisel, K., Duerig, J., Jauch, A., Peters-Regehr, T., Zorn, M., and Goldschmidt, H.

Published
2015

34. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

Author

Merz, M., primary, Salwender, H., additional, Haenel, M., additional, Mai, E. K., additional, Bertsch, U., additional, Kunz, C., additional, Hielscher, T., additional, Blau, I. W., additional, Scheid, C., additional, Hose, D., additional, Seckinger, A., additional, Jauch, A., additional, Hillengass, J., additional, Raab, M. S., additional, Schurich, B., additional, Munder, M., additional, Schmidt-Wolf, I. G. H., additional, Gerecke, C., additional, Lindemann, H.-W., additional, Zeis, M., additional, Weisel, K., additional, Duerig, J., additional, and Goldschmidt, H., additional

Published
2015
Full Text
View/download PDF

35. Recent Upgrade of the PITZ Facility

Author

Baehr, J. W., Al-Juboori, H., Khojoyan, M. A., Klemz, G., Koehler, W., Koss, G., Krasilnikov, M., Kretzschmann, A., Leich, H., Mahgoub, M., Meissner, J., Melkumyan, D., Donat, A., Otevrel, M., Penno, M., Petrosyan, B., Pohl, M., Rimjaem, S., Rueger, C., Sachwitz, M., Schoeneich, B., Schultze, J., Shapovalov, A., Gensch, U., Stephan, F., Tanha, M., Trowitzsch, G., Vashchenko, G., Vu, L. V., Walther, T., Wang, X., Weisse, S., Wenndorff, R., Winde, M., Grabosch, H.-J., Brinkmann, A., Floettmann, K., Lederer, S., Obier, F., Reschke, D., Schreiber, S., Saisut, J., Thongbai, C., Knobloch, J., Richter, D., Hakobyan, L., Michelato, P., Monaco, L., Pagani, C., Sertore, D., Asova, G., Bonev, I., Staykov, L., Tsakov, I. I., Sandner, W., Will, I., Haenel, M., Paramonov, V., Militsyn, B. L., Muratori, B., Korostelev, M., Vilaithong, T., Ackermann, W., Mueller, W. F. O., Schnepp, S., Weiland, T., Ullmann, I., Heller, R., Roensch-Schulenburg, J., Rossbach, J., Ivanisenko, Y., and Jachmann, L.

Published
2010

36. Bortezomib/cyclophosphamide/dexamethasone (VCD) is equally effective and has a favorable toxicity profile compared to bortezomib/doxorubicin/dexamethasone (PAd) as induction therapy in newly diagnosed, transplant-eligible myeloma patients: Results from the multicenter, phase III clinical trial GMMG-MM5

Author

Mai, E. K., Bertsch, U., Duerig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W, Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H., Goldschmidt, H., Mai, E. K., Bertsch, U., Duerig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W, Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H., and Goldschmidt, H.

Published
2014

38. Recent Emittance Measurements Results for the Upgraded PITZ Facility

Author

Rimjaem, S., Asova, G., Krasilnikov, M., Nozdrin, M., O'Shea, B., Otevrel, M., Petrosyan, B., Riemann, S., Roensch, J., Shapovalov, A., Spesyvtsev, R., Staykov, L., Baehr, J., Stephan, F., Vashchenko, G., Floettmann, K., Lederer, S., Schreiber, S., Richter, D., Will, I., Boulware, C., Grabosch, H. J., Haenel, M., Hakobyan, L., Ivanisenko, Y., Khojoyan, M., and Klemz, G.

Published
2009

39. Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)

Author

Jaekel, Nadia, Hubert, Karolin, Krahl, Rainer, Haenel, M, Maschmeyer, Georg, Herbst, Regina, Jakob, Christian, Schulze, Susann, Wang, Song-Yau, Cross, Michael, Kahl, Christoph, Wass, Maxi, Sayer, Herbert G., Brosteanu, Oana, Niederwieser, Dietger, and Al-Ali, Haifa Kathrin

Published
2017
Full Text
View/download PDF

40. BACOPP-D as treatment in patients with advanced Hodgkin lymphoma

Author

Naumann, R., Wetzko, K., Haenel, A., Friedrichsen, K., Zschuppe, E., Schmidt, H., Moelle, M., Dawel, M., Beuthien-Baumann, B., Schwanebeck, U., Ehninger, G., and Haenel, M.

Abstract

Introduction. The development of the escalated BEACOPP regimen let to an improved outcome in patients with advanced Hodgkin Lymphoma (HD9 study of the GHSG). However, the application of high dose etoposide (cumulative 4,8 g/m2 per 8 cycles) seems to be associated with an increased incidence of secondary MDS and AML, respectively. Therefore, the aim of our ongoing multicenter pilot study is to evaluate the efficacy and toxicity of the etoposide free as well as dose intensified BACOPP-D protocol. Methods. Since May 2000 a total of 115 patients with Hodgkin Lymphoma (HL) stage IIB, III, and IV were treated with BACOPP-D which included cyclophosphamide 1250 mg/m2 (d1), adriamycin 25 mg/m2(d1+2), dacarbazine 250 mg/m2 (d1-3), procarbazine 100 mg/m2 (d1-7), prednisolone 40 mg/m2 (d1-14), bleomycin 10 mg/m2(d8) and vincristine 1,4 mg/m2 (maximum 2 mg, d8) at three-weekly intervals with granulocyte colony-stimulating factor (G-CSF). A consolidating involved field radiation (30 Gy) was performed only in patients who achieved less than CR following chemotherapy. Initial staging and post-treatment control included PET monitoring. Results. Until now 97 patients (median age 35 years, range 17-65; 61 male, 36 female) are assessable for toxicity and treatment outcome. We analyzed the acute toxicity for 728 cycles of BACOPP-D. CTC/WHO grade III/IV haematological toxicities per patient were observed as follows: leukopenia 93%, anemia 39%, and thrombocytopenia 33%. CTC grade III/IV non-haematological side effects included documented infection (4%) and lung toxicity (one patient with reversible bleomycininduced pneumonitis). A total of 85 patients (88%) achieved complete remission, 9 patients (9%) achieved partial remission, three patients (3%) had progressive disease. At a median observation time of 39 months (0,9-77 months), six patients have relapsed, and nine deaths were documented (4 HL-specific and 3 treatment related deaths, 1 death due to ruptured Meckel diverticulum with peritonitis, one 65 year-old woman died in CR following myocardial infarction caused by coronary heart disease). One patient developed a second neoplasia (hypopharyngeal carcinoma in an alcoholic). The overall survival and freedom from treatment failure rates at 39 months were 91% and 85%, respectively. Discussion. BACOPP-D regimen appears as a feasible and safe treatment protocol with moderate acute toxicity in patients with advanced HL. No secondary AML or MDS occured until now.

Published
2007

42. BACOPP-D - An etoposide-free dose-escalated polychemotherapy regimen in advanced Hodgkin Lymphoma

Author

Naumann, R., Wetzko, K., Haenel, A., Friedrichsen, K., Zschuppe, E., Schmidt, H., Dawel, M., Beuthien-Baumann, B., Scbwanebeck, U., Ehninger, G., Haenel, M., Naumann, R., Wetzko, K., Haenel, A., Friedrichsen, K., Zschuppe, E., Schmidt, H., Dawel, M., Beuthien-Baumann, B., Scbwanebeck, U., Ehninger, G., and Haenel, M.

Abstract

Introduction: The development of the escalated BEACOPP regimen let to an improved outcome in patients with advanced Hodgkin Lymphoma (HD9 study of the GHSG). However, the application of high dose etoposide (cumulative 4,8 g/m2 per 8 cycles) seems to be associated with an increased incidence of secondary MDS and AML, respectively. Therefore, the aim of our multicenter pilot study was to evaluate the efficacy and toxicity of the etoposide free as well as dose intensified BACOPP-D protocol. Methods: Since May 2000 a total of 115 patients with Hodgkin Lymphoma (HL) stage IIB, III, and IV were treated with BACOPP-D which included cyclophosphamide 1250 mg/m2 (d1), adriamycin 25 mg/m2 (d1+2), dacarbazine 250 mg/m2 (d1-3), procarbazine 100 mg/m2 (d1-7), prednisolone 40 mg/m2 (d1-14), bleomycin 10 mg/m2 (d8) and vincristine 1,4 mg/m2 (maximum 2 mg, d8) at three-weekly intervals with granulocyte colony-stimulating factor (G-CSF). A consolidating involved field radiation (30 Gy) was performed only in patients who achieved less than CR following chemotherapy. Post-treatment follow-up included PET imaging. Results: Until now 97 patients (median age 35 years, range 17-65; 61 male, 36 female) are assessable for toxicity and treatment outcome. We analyzed the acute toxicity for 728 cycles of BACOPP-D. CTC/WHO grade III/IV haematological toxicities per patient were observed as follows: leukopenia 93%, anemia 39%, and thrombocytopenia 33%. CTC grade III/IV non-haematological side effects included documented infection (4%) and lung toxicity (one patient). A total of 85 patients (88%) achieved complete remission, 9 patients (9%) achieved partial remission, three patients (3%) had progressive disease. At a median observation time of 39 months (0,9-77 months), five patients have relapsed, and nine deaths were documented (4 HL-specific and 3 treatment related deaths, 1 death due to ruptured Meckel diverticulum with peritonitis, one 65 year-old woman died in CR following myocardial infarct

Published
2007

43. Systemic and intrathecal chemotherapy followed by high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT) for CNS relapse of aggressive lymphomas: A potentially curative approach?

Author

Fischer, L., primary, Haenel, M., additional, Moehle, R., additional, Schroers, R., additional, Elter, T., additional, Reiser, M., additional, Dreyling, M. H., additional, Illerhaus, G., additional, Eucker, J., additional, Scholz, C. W., additional, Metzner, B., additional, Roeth, A., additional, Birkmann, J., additional, Schlegel, U., additional, Martus, P., additional, Thiel, E., additional, and Korfel, A., additional

Published
2011
Full Text
View/download PDF

44. Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL).

Author

Schmitz, N., primary, Nickelsen, M., additional, Ziepert, M., additional, Haenel, M., additional, Borchmann, P., additional, Schmidt, C., additional, Viardot, A., additional, Bentz, M., additional, Peter, N., additional, Ehninger, G., additional, Doelken, G., additional, Truemper, L. H., additional, Loeffler, M., additional, Pfreundschuh, M., additional, and Glass, B., additional

Published
2011
Full Text
View/download PDF

50. Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

Author

Pfreundschuh, M., primary, Zeynalova, S., additional, Poeschel, V., additional, Haenel, M., additional, Schmitz, N., additional, Ho, A. D., additional, Reiser, M., additional, Loeffler, M., additional, and Schubert, J., additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results